RESUMEN
ObjectiveTo explore the clinical value of three serum tumor markers, Golgi protein 73 (GP73), alpha-fetoprotein (AFP), and AFP-L3, in the diagnosis of liver cancer and recurrence monitoring after radio frequency ablation. MethodsA total of 174 patients who visited our hospital from July 2012 to October 2013 were included in the study, consisting of 86 patients with newly diagnosed liver cancer, 39 with liver cirrhosis, 29 with hepatitis, and 20 healthy controls. Among the patients with newly diagnosed liver cancer, 37 were followed up for three months after the radiofrequency ablation. Serum levels of GP73, AFP, and AFP-L3 were measured by ELISA, electrochemiluminescence, and affinity adsorption chromatography, respectively. Nonparametric tests were performed on the results of serum samples from the four groups which showed skewed distribution and were represented by median (quartile interval) ［M(P25-P75)］. Overall comparison was made by Kruskal-Wallis H test, and comparison between groups was made by Mann-Whitney U test. Pair-matching rank-sum test was performed using Wilcoxon Signed Ranks, and categorical data were analyzed by χ2 test. ResultsThe levels of GP73, AFP, and AFP-L3 in the liver cancer group were significantly higher than those in other groups (all P＜0.05). The positive rates of GP73 and AFP-L3 in the liver cancer group were significantly higher than those in other groups (all P＜0.05), and the positive rates of the two markers were significantly higher than that of AFP among patients with liver cancer (P＜0.05). Thirty-seven patients with newly diagnosed liver cancer were reexamined three months after radiofrequency ablation, and the preoperational AFP-L3 level in the patients who had recurrence was significantly higher than that in the patients without recurrence (P＜0.05). ConclusionSerum GP73, AFP, and AFP-L3 show great values in the diagnosis of liver cancer. AFP-L3 can be used as an indicator for the identification of benign or malignant liver disease and risk of recurrence after radiofrequency ablation.
RESUMEN
Objective To investigate the value of combined detection of serum alpha-fetoprotein (AFP)and Golgi protein-73 (GP73)in the diagnosis of hepatocellular carcinoma (HCC)and to provide a basis for early diagnosis and differential diagnosis of HCC.Methods A total of 408 patients hospitalized in Baoji Central Hospital from June 2012 to May 2013,as well as healthy persons who had normal test re-sults in physical examination,were included in the study,and their specimens were collected.These patients were classified into HCC group (n=142),chronic hepatitis group (n=156),and liver cirrhosis group (n=110).Serum levels of AFP and GP73 in the three groups were measured by electrochemiluminescence immunoassay and double -antibody sandwich enzyme -linked immunosorbent assay,respectively. Comparison of test results between groups was made by analysis of variance,and comparison of rates was made by chi-square test.The sen-sitivity and specificity of the two indicators for the diagnosis of HCC were calculated using MedCalc statistical software.Results The HCC group had significantly higher serum AFP and GP73 levels than the liver cirrhosis group and chronic hepatitis group (P<0.05);the liver cirrhosis group had significantly higher serum AFP and GP73 levels than the chronic hepatitis group (P<0.05).The sensitivity and speci-ficity of the two indicators for the diagnosis of HCC were 95.8% and 98.6%,respectively,showing significant differences compared with those of each indicator alone (P<0.05).Conclusion Combined detection of serum AFP and GP73 has high diagnostic value and clinical significance for HCC,and they can be used as indicators for early diagnosis and differential diagnosis of HCC.